ELISA assays for IgM and IgG rheumatoid factors: Their clinical correlations during therapy with slow-acting anti-rheumatic drugs

Scott, David; Dawes, P. T.; Collins, Mary; Stone, RobertE.

doi:10.1007/bf02206834

Cited by 6 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A reduction of IgM RF, IgG RF, and IgA RF levels after 1 year of methotrexate treatment was also reported by Spadaro and co‐workers 22 . Other studies have evaluated the effect of penicillamine, gold salts, minocycline, and sulphasalazine on RF levels showing that treatment can decrease the production of IgM RF and, to a lesser extent, of IgA RF and IgG RF 7,21–24 . Recently, Mikuls et al showed a good correlation between clinical response and a drop in IgM RF levels in 64 patients treated with different DMARDs for about 1 year 23 …”

Section: Changes In Radiofrequency During Anti‐tnf‐α Therapymentioning

confidence: 57%

“…Various studies, carried out in the pre‐biological drug era, proved that effective DMARD therapy can decrease serum RF levels 14–22 . Olsen et al showed that blood mononuclear cells from RA patients with active disease produced in vitro high levels of IgM RF whereas the production of IgM RF was low or absent following treatment with DMARDs 16 .…”

Section: Changes In Radiofrequency During Anti‐tnf‐α Therapymentioning

confidence: 99%

See 1 more Smart Citation

Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients

Bobbio-Pallavicini

Caporali

Alpini

et al. 2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

This article will focus on the relationship between serum levels of anti-citrullinated peptide antibodies (anti-CCP) or rheumatoid factor (RF) and clinical response to TNF-alpha blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti-CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease. On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre-treatment RF positivity or negativity does not influence response to TNF-alpha blocking therapy while high pre-treatment levels of IgA RF seem to be associated with a poor response rate.

show abstract

Section: Changes In Radiofrequency During Anti‐tnf‐α Therapymentioning

confidence: 57%

Section: Changes In Radiofrequency During Anti‐tnf‐α Therapymentioning

confidence: 99%

Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients

Bobbio-Pallavicini

Caporali

Alpini

et al. 2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…Several studies have documented that the level of IgM‐RF decreases with the administration of effective disease‐modifying therapies (6–11). In contrast, few studies have examined the impact of active RA treatments on the level of anti‐CCP antibodies (6, 10, 11).…”

mentioning

confidence: 99%

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti–cyclic citrullinated peptide antibody

Mikuls

O'Dell

Stoner

et al. 2004

Arthritis & Rheumatism

107

View full text Add to dashboard Cite

Objective. To examine the association of treatment response and disease duration with changes in rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody levels among patients with rheumatoid arthritis (RA).Methods. The study sample included 66 RA patients who completed double-blind, randomized clinical protocols and for whom baseline and followup serum samples were available. Anti-CCP and RF levels were measured using commercially available assay kits. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to describe the association of response and disease duration with declines in antibody levels.Results. Patients had a mean ؎ SD age of 49.9 ؎ 12.0 years and were predominantly female (n ‫؍‬ 51; 77%). The mean ؎ SD duration between the times at which the baseline and followup serum samples were obtained was 13.7 ؎ 8.6 months. Among the 64 subjects with positive antibody at baseline, 33 (52%) experienced a >25% reduction in the anti-CCP antibody level during the course of treatment, and 35 patients (55%) had a >25% reduction in RF. After adjustment for the baseline anti-CCP antibody level, only a shorter disease duration (<12 months) was significantly associated with a decline in the level of anti-CCP antibody (OR 3.0, 95% CI 1.0-8.8), and no association with treatment response was observed. Conversely, treatment response was the only significant determinant of a decrease in RF levels (OR 3.6, 95% CI 1.2-10.4).Conclusion. Shorter disease duration predicts greater declines in anti-CCP antibody levels with treatment in RA. Although treatment response is a robust determinant of a decrease in RF, it does not appear to be associated with declines in the anti-CCP antibody level.

show abstract

“…[35][36][37] There is a slow change in RhF in association with diseasemodifying drugs such as penicillamine. This drop, although important, does not correlate with changes in ESR or joint score.…”

Section: Rheumatoid Factor and Human Leucocyte Antigen B27 In The Invmentioning

confidence: 99%

“…This drop, although important, does not correlate with changes in ESR or joint score. [35][36][37] Possible reasons for this poor correlation are:…”

Section: Rheumatoid Factor and Human Leucocyte Antigen B27 In The Invmentioning

confidence: 99%

Best practice in primary care pathology: review 6: Figure 1

Smellie

Forth²,

Coleman

et al. 2006

J Clin Pathol

View full text Add to dashboard Cite

This sixth best practice review examines four series of common primary care questions in laboratory medicine: (1) laboratory monitoring in hypertension and heart failure abnormalities; (2) markers of inflammatory joint disease; (3) laboratory investigation of chronic diarrhoea; and (4) mumps and chickenpox. The review is presented in question-answer format, referenced for each question series. The recommendations represent a precis of guidance found using a standardised literature search of national and international guidance notes, consensus statements, health policy documents and evidence-based medicine reviews, supplemented by Medline Embase searches to identify relevant primary research documents. They are not standards but form a guide to be set in the clinical context. Most are consensus based rather than evidence based. They will be updated periodically to take account of new information.

show abstract

ELISA assays for IgM and IgG rheumatoid factors: Their clinical correlations during therapy with slow-acting anti-rheumatic drugs

Cited by 6 publications

References 31 publications

Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients

Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti–cyclic citrullinated peptide antibody

Best practice in primary care pathology: review 6: Figure 1

Contact Info

Product

Resources

About